drugset / Trial / NCT01498172
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
Phase 1
Completed
23 enrolled
Patrice Jichlinski
GlaxoSmithKline · collabLudwig Center for Cancer Research of Lausanne · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
In this study, the investigators would like to assess how intravesical BCG schedules after immunization of non muscle invasive bladder patients with the recMAGE-A3 protein, together with adjuvant AS15 (recMAGE-A3 + AS15 ASCI), may enhance innate and vaccine-specific T cell responses both systemically and locally in the bladder.
Timeline
- Start
- 2012-01
- Primary completion
- 2015-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCG | Unknown | — | Other |
| Subject | GSK1572932A | Protein / enzyme biologic | — | — |